Preprint
Review

This version is not peer-reviewed.

Adjuvant Radiotherapy After Surgical Excision of Desmoplastic Melanoma: A Systematic Review of Local Control and Survival Outcomes

Submitted:

11 December 2025

Posted:

12 December 2025

You are already at the latest version

Abstract
Desmoplastic melanoma (DM) is a rare, aggressive melanoma subtype with high local recurrence rates (20-60%) following surgical excision. This systematic review evaluated the efficacy of adjuvant radiotherapy (RT) in improving local control and survival outcomes in DM patients. Following Preferred reporting items for systematic review and meta-analyses (PRISMA) guidelines, we searched PubMed/MEDLINE, ScienceDirect, Scopus, CINAHL, and EBSCO databases from inception through December 2025.. Thirteen studies (10 retrospective cohorts, 3 prospective trials) met the inclusion criteria. quality assessment using JBI tools revealed 69% high quality and 31% moderate quality studies. Adjuvant RT significantly reduced local recurrence rates from 17.2% (surgery alone) to 7.6% (surgery plus RT), representing a 56% relative risk reduction. All hypofractionated RT (e.g. 30 Gy/5 fractions) achieved comparable local control rates (90-95% at 5 years). High-risk features including positive margins, Breslow depth ˃4 mm, and neurotropism identified patients deriving greatest benefits from RT. Adjuvant radiotherapy significantly improves local control in DM following surgical excision and should be considered standardized of care for high-risk patients. Future randomized trials are needed to established definitive treatment.
Keywords: 
;  ;  ;  ;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated